MIRA Pharmaceuticals Announces Preclinical Results Showing Ketamir-2 Does Not Induce Hyper-Locomotor Activity
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals announced preclinical results indicating that their compound Ketamir-2 does not induce hyper-locomotor activity, which is a positive safety indicator for the drug's development.
June 24, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals announced that their compound Ketamir-2 does not induce hyper-locomotor activity in preclinical trials, which is a positive safety indicator for the drug's development.
The announcement of positive preclinical results for Ketamir-2 is likely to boost investor confidence in MIRA Pharmaceuticals, as it indicates a favorable safety profile for the drug. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100